Literature DB >> 25914473

Comparison of hepatic resection and transarterial chemoembolization for solitary hepatocellular carcinoma.

Dong-Zhi Zhang1, Xiao-Dong Wei1, Xiao-Peng Wang1.   

Abstract

AIM: To compare the outcomes of hepatic resection and transarterial chemoembolization (TACE) for solitary hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer (BCLC) staging system.
METHODS: A consecutive sample of 540 patients with solitary HCC who underwent liver resection (n = 312) or TACE (n = 128) were included in the present study. Baseline characteristics, tumor characteristics, and post-operative complications were compared between the two groups. The Kaplan-Meier method was used for long-term survival analysis. Independent prognostic predictors were identified using the Cox proportional hazards model (univariate and multivariate analyses).
RESULTS: The TACE and liver resection groups had similar baseline demographic and clinicopathological characteristics. The TACE group showed a significantly lower rate of major complications than the liver resection group (3.9% vs 17.4%, P < 0.001). Univariate and multivariate analyses indicated that TACE did not contribute to poor overall survival compared with liver resection; however, a solitary tumor diameter of greater than 6 cm should be considered a risk factor for poor overall survival (HR = 1.328, 95%CI: 1.002-1.783, P = 0.048). The liver resection and TACE groups had comparable overall survival rates at 1 year, 3 years, and 5 years (86.2%, 62.8%, and 44.0% vs 88.3%, 59.8%, and 40.6%, respectively, P = 0.419). In cases with tumor diameters equal to or less than 6 cm, the liver resection group showed a survival benefit compared with the TACE group at 1 year, 3 years, and 5 years (P = 0.030). The 1-, 3-, and 5-year overall survival rates of HCC cases with tumor diameters of more than 6 cm were similar among the liver resection and TACE groups (P = 0.467).
CONCLUSION: A tumor diameter of 6 cm should be the cutoff for deciding between liver resection and TACE.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver resection; Solitary; Transarterial chemoembolization

Mesh:

Year:  2015        PMID: 25914473      PMCID: PMC4402311          DOI: 10.3748/wjg.v21.i15.4635

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  Liver Cancer Working Group report.

Authors:  Masatoshi Kudo; Kwang Hyub Han; Norihiro Kokudo; Ann-Lii Cheng; Byung Ihn Choi; Junji Furuse; Namiki Izumi; Joong-Won Park; Ronnie T Poon; Michiie Sakamoto
Journal:  Jpn J Clin Oncol       Date:  2010-09       Impact factor: 3.019

Review 2.  Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

Authors:  Masatoshi Kudo; Hobyung Chung; Yukio Osaki
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?

Authors:  Gerd Otto; Marcus Schuchmann; Maria Hoppe-Lotichius; Michael Heise; Arndt Weinmann; Torsten Hansen; Michael P Pitton
Journal:  J Hepatol       Date:  2013-04-12       Impact factor: 25.083

7.  Comparison between hepatic resection and radiofrequency ablation as first-line treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less.

Authors:  Kastunori Imai; Toru Beppu; Akira Chikamoto; Koichi Doi; Hirohisa Okabe; Hiromitsu Hayashi; Hidetoshi Nitta; Takatoshi Ishiko; Hiroshi Takamori; Hideo Baba
Journal:  Hepatol Res       Date:  2013-01-02       Impact factor: 4.288

Review 8.  Hepatocellular carcinoma: clinical frontiers and perspectives.

Authors:  Jordi Bruix; Gregory J Gores; Vincenzo Mazzaferro
Journal:  Gut       Date:  2014-02-14       Impact factor: 23.059

Review 9.  TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications.

Authors:  Silvana C Faria; Janio Szklaruk; Ahmed O Kaseb; Hesham M Hassabo; Khaled M Elsayes
Journal:  Abdom Imaging       Date:  2014-10

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  5 in total

1.  Prediction of early recurrence of hepatocellular carcinoma after resection based on Gd-EOB-DTPA enhanced magnetic resonance imaging: a preliminary study.

Authors:  Qi-Yu Zhao; Shi-Shun Liu; Ming-Xin Fan
Journal:  J Gastrointest Oncol       Date:  2022-04

2.  Thymosin alpha-1 therapy improves postoperative survival after curative resection for solitary hepatitis B virus-related hepatocellular carcinoma: A propensity score matching analysis.

Authors:  He Linye; Xia Zijing; Peng Wei; He Chao; Li Chuan; Wen Tianfu
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

3.  Comparison of open liver resection and RFA for the treatment of solitary 3-5-cmhepatocellular carcinoma: a retrospective study.

Authors:  Lei Jianyong; Yan Lunan; Li Dajiang; Wang Wentao
Journal:  BMC Surg       Date:  2019-12-16       Impact factor: 2.102

4.  Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.

Authors:  Miao-Ling Chen; Chun-Xue Wu; Jian-Bo Zhang; Hao Zhang; Yuan-Dong Sun; Shi-Lin Tian; Jian-Jun Han
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

5.  Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis.

Authors:  Ramya Ramaswami; David J Pinato; Keiichi Kubota; Mitsuru Ishizuka; Tadaaki Arizumi; Masatoshi Kudo; Jeong Won Jang; Young Woon Kim; Mario Pirisi; Elias Allara; Rohini Sharma
Journal:  Med Oncol       Date:  2016-09-06       Impact factor: 3.064

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.